Difference between revisions of "Research budget in pharmaceutical industry"
Jump to navigation
Jump to search
Peter Friedl (talk | contribs) |
Peter Friedl (talk | contribs) |
||
| Line 8: | Line 8: | ||
* Marketability of pharmaceuticals | * Marketability of pharmaceuticals | ||
* Intellectual Property rights for pharmaceuticals (link to driving force [[IP rights]]) | * Intellectual Property rights for pharmaceuticals (link to driving force [[IP rights]]) | ||
* Funding of the health system | * Funding of R&D projects by the health system | ||
* General prosperity | * General prosperity | ||
==Inhibitors:== | ==Inhibitors:== | ||
* Unstable and unpredictable general economic conditions | * Unstable and unpredictable general economic conditions | ||
Revision as of 14:47, 18 September 2009
This page is under construction and edited by Peter Friedl EMBA09. In case of any questions/remarks, feel free to contact me
Description:
In the pharmaceutical industry research and development is a very time-consuming and demanding task. Only a few new drugs make it through development, testing and product approval each year. This asks for a large R&D budget over several years for pharmaceutical companies. Even then a success, the development of a new, good selling drug, is of course not guaranteed.
Enablers:
- Size of the pharmaceutical company
- Revenue streams of the company
- Marketability of pharmaceuticals
- Intellectual Property rights for pharmaceuticals (link to driving force IP rights)
- Funding of R&D projects by the health system
- General prosperity
Inhibitors:
- Unstable and unpredictable general economic conditions
Paradigms:
R&D in pharmaceutical industry is a very time and money consuming undertaking that requires predictable future revenue streams to be viable for the respective companies
Experts:
Timing:
Web Resources:
- [1] Pharmaceutical Corporations and Medical Research - article on Global Issues
- [2] R&D in the Pharmaceutical Industry - a Congressional Budget Office Study